Investor Relations

Data as of Sep 20, 2021 4:39 PM EDT

PRESS RELEASES

September 10, 2021

Summary Toggle Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
September 7, 2021

Summary Toggle Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated,
July 7, 2021

Summary Toggle Akari Therapeutics Announces Private Placement

NEW YORK and LONDON, July 07, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are

Company Presentation – July 2021

July 30, 2021

Company Presentation – July 2021 2.3 MB
Extract of Tim Higenbottam's presentation at the ARDS Drug Development Summit 2021

July 29, 2021

Extract of Tim Higenbottam's presentation at the ARDS Drug Development Summit 2021 633.4 KB
American Academy of Dermatology Association (AAD) Meeting April 2021 poster

April 23, 2021

American Academy of Dermatology Association (AAD) Meeting April 2021 poster 375.5 KB